Aurobindo Pharma Arm Eugia Gets Usfda Nod For Dasatinib Tablets, Eyes $1.8 Billion Market

SUMMARY

Aurobindo Pharma Ltd's wholly-owned subsidiary Eugia Pharma Specialities Ltd connected Wednesday said it received last support from nan US Food & Drug Administration (USFDA) to manufacture and marketplace Dasatinib Tablets successful 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg strengths.

These products are bioequivalent and therapeutically balanced to Sprycel Tablets by Bristol-Myers Squibb and are expected to beryllium launched successful nan first 4th of fiscal twelvemonth 2026, the institution stated successful a BSE filing.

The approved merchandise has an estimated marketplace size of US$ 1.8 cardinal for nan 12 months ending February 2025, according to IQVIA MAT.

This support marks nan 181st Abbreviated New Drug Application (ANDA) support for Eugia Pharma Specialities Group, which includes 9 tentative approvals.

Dasatinib Tablets are utilized for treating recently diagnosed adults pinch Philadelphia chromosome-positive chronic myeloid leukaemia successful nan chronic phase. They are besides utilized successful adults pinch chronic, accelerated, aliases myeloid aliases lymphoid blast shape Ph+ chronic myeloid leukaemia pinch guidance aliases intolerance to anterior therapies, including imatinib.

Additionally, Dasatinib Tablets are indicated for adults pinch Philadelphia chromosome-positive acute lymphoblastic leukaemia, facing guidance aliases intolerance to anterior therapies.

Stock-wise, Aurobindo Pharma was up 2.65 per cent astatine Rs 1,219.60. At this price, it has slipped 9.75 per cent successful nan almanac twelvemonth 2025 truthful far. 

Technically, nan scrip traded higher than nan 5-day, 10-, 20-, 30-, 50-day and 100-day elemental moving averages (SMAs) but little than nan 150-day and 200-day SMAs. Its 14-day comparative spot scale (RSI) came astatine 61.77. A level beneath 30 is defined arsenic oversold while a worth supra 70 is considered overbought.

As per BSE, nan banal has a price-to-equity (P/E) ratio of 36.91 against a price-to-book (P/B) worth of 3.60. Earnings per stock (EPS) stood astatine 33.01 pinch a return connected equity (RoE) of 9.75. As per Trendlyne, Auropharma has a one-year beta of 0.8, indicating debased volatility connected nan counter.

As of March 2025, promoters held a 51.82 per cent liking successful nan pharma firm.

Published on: Apr 23, 2025 12:22 PM IST